Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 4.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,488 shares of the biopharmaceutical company’s stock after selling 3,475 shares during the quarter. SG Americas Securities LLC owned 0.07% of Revance Therapeutics worth $223,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. FNY Investment Advisers LLC boosted its stake in shares of Revance Therapeutics by 160.4% in the fourth quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after buying an additional 294,323 shares in the last quarter. Exome Asset Management LLC purchased a new stake in shares of Revance Therapeutics during the 3rd quarter worth $1,804,000. Oddo BHF Asset Management Sas purchased a new stake in shares of Revance Therapeutics during the 3rd quarter worth $3,763,000. Virtu Financial LLC acquired a new position in shares of Revance Therapeutics during the 3rd quarter worth $120,000. Finally, Wellington Management Group LLP purchased a new position in shares of Revance Therapeutics in the 3rd quarter valued at about $2,315,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Stock Performance

Revance Therapeutics stock opened at $3.65 on Friday. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $7.56. The company has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The stock has a fifty day moving average of $3.39 and a two-hundred day moving average of $4.58.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. On average, analysts forecast that Revance Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on RVNC shares. HC Wainwright reissued a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Mizuho decreased their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Barclays dropped their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. StockNews.com started coverage on Revance Therapeutics in a research report on Thursday. They set a “hold” rating on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Revance Therapeutics has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.